Similar articles

• OKT3 first-line treatment of acute rejection episodes following combined pancreas and kidney transplantation.

  Cantarovich D, Hourmant M, Dantal J, Giral M, Paineau J, Karam G, Soulillou JP. Cantarovich D, et al. Transplant Proc. 1994 Apr;26(2):549. Transplant Proc. 1994. PMID: 8171548 No abstract available.
• Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.

  Alloway RR, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO. Alloway RR, et al. Transplant Proc. 1996 Apr;28(2):995-7. Transplant Proc. 1996. PMID: 8623494 Clinical Trial. No abstract available.
• Tacrolimus-based vs cyclosporine-based immunotherapy in combined kidney-pancreas transplantation.

  Ketel BL, Turton-Weeks S, Reed K, Barone GW. Ketel BL, et al. Transplant Proc. 1996 Apr;28(2):899. Transplant Proc. 1996. PMID: 8623453 No abstract available.
• Use of antilymphocyte induction therapy in liver transplantation: A European perspective.

  Langrehr JM, Neuhaus PJ. Langrehr JM, et al. Liver Transpl Surg. 1999 Jul;5(4 Suppl 1):S71-84. doi: 10.1053/JTLS005s00071. Liver Transpl Surg. 1999. PMID: 10431020 Review. No abstract available.
• Biological immunosuppressants: the way to clinical transplantation tolerance.

  Chatenoud L. Chatenoud L. Transplant Proc. 1997 Feb-Mar;29(1-2):51-5. doi: 10.1016/s0041-1345(96)00719-1. Transplant Proc. 1997. PMID: 9123108 Review. No abstract available.